almost
year
global
influenza
surveil
respons
system
gisr
key
player
monitor
evolut
spread
influenza
virus
recommend
strain
use
human
influenza
vaccin
gisr
also
work
continu
monitor
assess
risk
pose
potenti
pandem
virus
guid
appropri
public
health
respons
expand
enhanc
role
gisr
follow
adopt
intern
health
regul
recognit
continu
threat
pose
avian
aftermath
pandem
provid
opportun
time
critic
review
process
influenza
vaccin
virus
select
addit
identifi
potenti
area
improv
review
also
help
promot
greater
appreci
wider
influenza
policymak
commun
complex
influenza
vaccin
viru
select
select
process
highli
coordin
involv
continu
yearround
integr
virolog
data
epidemiolog
inform
nation
influenza
centr
nic
thorough
antigen
genet
character
virus
collabor
centr
whocc
part
select
suitabl
candid
vaccin
virus
prepar
suitabl
reassort
correspond
reagent
vaccin
standard
essenti
regulatori
laboratori
erl
ensur
optim
effect
vaccin
assist
recent
year
advanc
molecular
diagnosi
avail
extens
genet
sequenc
data
howev
remain
number
challeng
constraint
includ
variat
assay
use
possibl
complic
result
nonantigen
chang
limit
avail
suitabl
vaccin
virus
requir
recommend
made
year
advanc
peak
influenza
season
product
constraint
effect
collabor
coordin
human
anim
influenza
network
increasingli
recogn
essenti
requir
improv
integr
data
anim
human
virus
identif
unusu
influenza
virus
infect
human
evalu
pandem
risk
select
candid
virus
pandem
vaccin
train
workshop
assess
donat
led
signific
increas
train
laboratori
personnel
equip
result
expans
geograph
surveil
coverag
capac
nic
laboratori
result
signific
increas
volum
inform
report
spread
intens
impact
influenza
addit
initi
shipment
fund
project
facilit
time
share
clinic
specimen
viru
isol
contribut
comprehens
understand
global
distribut
tempor
circul
differ
virus
import
sustain
build
upon
gain
made
area
although
haemagglutin
inhibit
hai
assay
like
remain
assay
choic
antigen
character
virus
forese
futur
altern
assay
exampl
base
upon
advanc
recombin
dna
protein
technolog
may
adapt
autom
technolog
microtitr
neuraminidas
inhibit
assay
may
also
signific
implic
vaccin
viru
select
vaccin
develop
microneutr
assay
provid
import
adjunct
hai
assay
viru
antigen
character
improv
use
potenti
autom
assay
facilit
largescal
serolog
studi
advanc
techniqu
epitop
map
allow
accur
assess
qualiti
protect
immun
respons
aid
develop
addit
criteria
measur
immun
standard
seroepidemiolog
survey
assess
impact
influenza
popul
could
help
establish
wellcharacter
bank
agestratifi
repres
sera
nation
region
global
resourc
provid
direct
evid
specif
benefit
vaccin
advanc
highthroughput
genet
sequenc
coupl
advanc
bioinformat
tool
togeth
xray
crystallograph
data
acceler
understand
genet
phenotyp
chang
underli
viru
evolut
specif
help
predict
influenc
amino
acid
chang
viru
antigen
complex
mathemat
model
techniqu
increasingli
use
gain
insight
evolut
epidemiolog
influenza
virus
howev
valu
predict
time
natur
futur
antigen
genet
chang
like
limit
present
applic
simpler
nonmechanist
statist
algorithm
alreadi
use
basi
antigen
cartographi
phylogenet
model
like
use
facilit
vaccin
viru
select
aid
assess
pandem
potenti
avian
anim
influenza
virus
adopt
altern
vaccin
technolog
liveattenu
quadrival
nonhabas
vaccin
signific
implic
vaccin
viru
select
well
vaccin
regulatori
manufactur
process
recent
collabor
gisr
vaccin
manufactur
result
increas
avail
egg
isol
highgrowth
reassort
vaccin
product
develop
qualifi
cell
cultur
investig
altern
method
vaccin
potenc
test
continu
support
effort
increas
reliabl
timeli
global
influenza
vaccin
suppli
gisr
partner
continu
work
identifi
improv
har
new
technolog
strengthen
sustain
collabor
continu
central
role
coordin
worldwid
expertis
meet
increas
public
health
need
influenza
vaccin
support
effort
improv
vaccin
viru
select
process
includ
conven
period
intern
consult
histor
initi
establish
global
network
detect
identifi
new
potenti
danger
influenza
virus
predat
adopt
constitut
memori
influenza
pandem
still
vivid
everevolv
threat
pose
influenza
recogn
global
influenza
surveil
respons
system
gisr
formal
establish
influenza
thu
becam
one
first
diseas
highlight
import
intern
monitor
collabor
protect
human
health
follow
reemerg
human
case
highli
pathogen
avian
influenza
adopt
intern
health
regul
gisr
strengthen
role
protect
public
health
enhanc
addit
track
cours
impact
annual
influenza
epidem
monitor
evolut
season
influenza
virus
gisr
also
act
global
alert
mechan
emerg
influenza
virus
potenti
caus
human
pandem
network
provid
support
season
pandem
influenza
prepared
respons
activ
area
diagnost
vaccin
develop
virolog
surveil
risk
assess
also
act
focu
effort
former
global
influenza
surveil
network
gisn
renam
global
influenza
surveil
respons
system
gisr
sinc
may
world
health
assembl
resolut
wha
adopt
assist
member
state
strengthen
nation
capac
surveil
diagnosi
character
share
influenza
virus
key
player
global
influenza
risk
assess
respons
gisr
continu
evolv
expand
decemb
consist
nation
influenza
centr
nic
countri
six
collabor
centr
whocc
refer
laboratori
four
essenti
regulatori
laboratori
erl
gisr
also
work
ensur
success
coordin
activ
extern
agenc
global
outbreak
alert
respons
network
goarn
nation
regulatori
author
academ
veterinari
institut
pharmaceut
industri
first
formal
recommend
influenza
vaccin
composit
issu
sinc
separ
appropri
time
recommend
northern
southern
hemispher
issu
year
februari
septemb
respect
biannual
recommend
base
upon
virolog
epidemiolog
inform
gener
gisr
play
crucial
role
develop
product
avail
effect
influenza
vaccin
continu
threat
pose
avian
aftermath
pandem
increas
knowledg
influenza
develop
avail
new
technolog
provid
time
opportun
review
complex
process
issu
involv
influenza
vaccin
viru
select
identifi
potenti
area
improv
inform
consult
repres
latest
step
ongo
process
gisr
strengthen
conven
follow
object
review
current
vaccin
viru
select
process
includ
constraint
limit
identifi
opportun
improv
influenza
surveil
repres
viru
share
assess
potenti
improv
assay
technolog
use
vaccin
viru
select
assess
potenti
impact
new
vaccin
technolog
vaccin
viru
select
process
particip
drawn
broad
highli
divers
rang
institut
sector
includ
follow
whocc
nic
erl
refer
laboratori
nation
regulatori
author
public
health
agenc
academia
influenza
vaccin
manufactur
veterinari
laboratori
organ
primari
goal
gisr
vaccin
viru
select
process
annex
gener
analys
data
need
recommend
influenza
vaccin
virus
close
match
influenza
virus
like
circul
forthcom
influenza
season
current
vaccin
technolog
product
schedul
mean
decis
vaccin
composit
made
almost
full
year
advanc
peak
season
influenza
activ
result
process
reli
upon
earliest
possibl
detect
emerg
antigen
variant
uptod
inform
potenti
futur
epidemiolog
signific
inform
must
therefor
collect
year
round
continu
evolut
global
circul
human
influenza
virus
provid
sound
basi
biannual
recommend
composit
influenza
vaccin
use
northern
southern
hemispher
countri
equatori
region
epidemiolog
consider
influenc
recommend
februari
septemb
individu
nation
region
author
consid
appropri
nation
influenza
centr
nic
play
vital
role
complex
process
core
activ
includ
collat
epidemiolog
inform
diagnos
case
influenza
b
infect
identifi
subtyp
lineag
virus
respons
primarili
molecular
diagnosi
infect
use
rtpcr
techniqu
base
upon
standard
primer
probe
provid
gisr
virus
must
also
isol
allow
antigen
identif
use
typeand
subtypespecif
refer
reagent
provid
annual
distribut
kit
detail
character
may
includ
sequenc
analys
monitor
genet
chang
assess
virolog
trait
resist
antivir
drug
sequenc
data
share
within
gisr
use
public
databas
genbank
gisaid
epiflu
nic
set
attempt
relat
potenti
import
virolog
chang
observ
clinic
epidemiolog
inform
trend
may
even
conduct
serolog
studi
evalu
immun
statu
popul
weekli
report
virolog
characterist
epidemiolog
circul
virus
submit
flunet
internetbas
dataqueri
report
tool
inform
viru
subtyp
lineag
collat
togeth
observ
potenti
clinic
epidemiolog
import
regular
summari
geograph
spread
intens
impact
influenza
produc
human
infect
avian
anim
influenza
viru
suspect
suitabl
equip
nic
nation
influenza
refer
laboratori
conduct
preliminari
diagnost
test
use
rtpcr
protocol
reagent
subtyp
provid
rtpcr
test
requir
highlevel
biocontain
facil
howev
expect
detect
unusu
influenza
viru
distinct
known
circul
virus
especi
one
suspect
anim
origin
unsubtyp
use
current
reagent
immedi
report
collabor
urgent
initi
collabor
centr
whocc
requir
laboratori
biosafeti
facil
procedur
avail
viru
isol
attempt
nation
laboratori
sampl
promptli
sent
whocc
routin
time
share
repres
circul
influenza
virus
unusu
virus
whocc
essenti
step
vaccin
viru
select
process
criteria
forward
virus
includ
tempor
geograph
agegroup
distribut
sever
case
virolog
characterist
unidentifi
subtyp
antivir
drug
resist
whocc
respons
systemat
antigen
character
thousand
virus
forward
year
nic
laboratori
detail
genet
character
select
subset
detail
antigen
genet
character
necessari
step
monitor
viru
evolut
detect
distinct
antigen
variant
may
necessit
updat
season
vaccin
composit
process
also
allow
identif
character
anim
virus
caus
sporad
human
infect
assess
risk
pose
potenti
develop
candid
vaccin
virus
part
pandem
prepared
prime
import
immun
influenza
product
antibodi
viru
haemagglutinin
ha
protein
antibodi
neutral
infect
virus
level
blood
shown
correl
level
protect
infect
homolog
viru
result
influenza
vaccin
viru
select
primarili
base
upon
antigen
character
viru
ha
use
haemagglutin
inhibit
hai
assay
hai
test
provid
visual
readout
abil
specif
antibodi
prevent
attach
ha
red
blood
cell
rbc
thu
prevent
agglutin
antigen
drift
ha
circul
virus
respons
host
immun
reduc
effect
vaccin
therefor
major
consider
recommend
made
composit
influenza
vaccin
hai
test
like
remain
assay
choic
antigen
character
viru
ha
forese
futur
strainspecif
antisera
produc
infect
previous
unexpos
naiv
ferret
either
vaccin
virus
refer
virus
repres
circul
virus
virus
appear
hai
test
potenti
antigen
variant
result
set
refer
virus
antisera
use
evalu
antigen
characterist
recent
isol
antigen
differ
detect
like
affect
human
immun
new
variant
hai
test
surrog
complic
timeconsum
viru
neutral
assay
use
clarifi
antigen
relationship
observ
variat
hai
titr
reflect
exampl
chang
receptor
bind
rather
differ
antigen
subset
virus
receiv
select
genet
sequenc
detail
analysi
princip
ha
na
compon
subset
select
includ
repres
circul
virus
well
appar
antigen
variant
virus
sever
fatal
case
phylogenet
analys
carri
better
understand
evolut
circul
virus
degre
genet
heterogen
emerg
new
genet
clade
antigen
phenotyp
variant
may
thu
defin
term
separ
genet
clade
distinct
amino
acid
signatur
relat
locat
amino
acid
substitut
antigen
receptorbind
glycosyl
site
structur
ha
molecul
help
identifi
individu
substitut
associ
phenotyp
antigen
chang
identifi
amino
acid
signatur
also
facilit
global
monitor
emerg
distribut
impact
differ
genet
variant
particularli
help
data
emerg
variant
limit
time
vaccin
consult
comparison
sequenc
found
clinic
specimen
viru
isol
also
use
reveal
amino
acid
substitut
result
passag
differ
substrat
mainli
mdck
cell
egg
uptod
sequenc
data
share
within
gisr
made
public
avail
via
gisaid
epiflu
databas
complet
genom
sequenc
necessari
identifi
anim
includ
avian
virus
caus
human
infect
import
detect
emerg
reassort
virus
among
cocircul
human
virus
human
anim
virus
whocc
maintain
panel
refer
reagent
influenza
subtyp
includ
especi
avian
virus
variou
swine
virus
well
virus
present
anim
hors
dog
whocc
also
collabor
erl
serolog
studi
repres
human
sera
previous
vaccin
individu
sera
provid
vaccin
manufactur
use
hai
test
assess
whether
antibodi
induc
current
vaccin
like
effect
current
circul
virus
result
princip
criteria
use
decid
whether
recommend
chang
influenza
vaccin
compon
includ
emerg
antigen
genet
distinct
variant
among
circul
virus
includ
novel
influenza
viru
potenti
caus
pandem
evid
geograph
spread
distinct
variant
associ
outbreak
diseas
indic
futur
epidemiolog
signific
reduc
abil
exist
vaccineinduc
antibodi
neutral
emerg
variant
avail
suitabl
candid
vaccin
virus
facilit
collabor
studi
whocc
erl
ensur
appropri
potenti
candid
vaccin
virus
identifi
advanc
vaccin
composit
consult
recent
virolog
epidemiolog
data
share
discuss
via
teleconfer
held
week
consult
summari
teleconfer
promptli
distribut
keep
nic
vaccin
manufactur
inform
develop
situat
addit
potenti
candid
vaccin
virus
provid
manufactur
formal
biannual
consult
technic
advisori
group
consid
cumul
antigen
genet
data
virus
character
whocc
data
set
broader
epidemiolog
context
collat
support
serolog
data
whocc
erl
well
addit
inform
provid
nic
hai
data
obtain
differ
centr
use
wide
varieti
refer
virus
ferret
antisera
correl
use
common
refer
reagent
recent
year
antigen
cartographi
use
collat
statist
visual
degre
antigen
variat
interpret
hai
data
may
howev
complic
influenc
chang
receptorbind
properti
natur
virus
select
variant
isol
passag
differ
cell
egg
substrat
comparison
sequenc
data
made
relat
differ
antigen
specif
ha
genet
clade
precis
defin
ident
antigen
variant
result
viru
neutral
test
usual
correspond
hai
test
use
clarifi
true
antigen
relationship
differ
virus
antigen
data
support
genet
serolog
data
indic
new
antigen
variant
spread
global
chang
compon
season
vaccin
consid
warrant
implement
recommend
updat
vaccin
compon
howev
conting
upon
avail
suitabl
vaccin
virus
factor
taken
account
decis
taken
whether
recommend
chang
influenza
vaccin
viru
composit
decis
announc
inform
meet
immedi
follow
consult
publish
web
site
weekli
epidemiolog
record
sinc
reemerg
human
case
highli
pathogen
avian
influenza
also
regularli
review
avail
antigen
genet
data
human
avian
virus
relat
epidemiolog
influenza
among
bird
support
develop
safe
effect
human
vaccin
coordin
develop
number
candid
attenu
vaccin
virus
annex
made
avail
vaccin
produc
clinic
trial
conduct
evalu
immunogen
differ
vaccin
formul
breadth
antibodi
respons
elicit
addit
part
pandem
prepared
coordin
ongo
develop
updat
inventori
candid
vaccin
virus
import
constraint
vaccin
viru
select
process
includ
tight
timelin
involv
annex
particularli
northern
hemispher
sinc
recent
year
season
influenza
activ
tend
start
increas
middl
late
januari
gener
consequ
decis
often
made
rel
earli
influenza
season
addit
postinfect
ferret
antisera
potenti
antigen
variant
urgent
requir
defin
antigen
relationship
previous
circul
virus
panel
recent
isol
must
also
prepar
assess
degre
neutral
antibodi
sera
previous
vaccin
individu
final
potenti
new
candid
vaccin
virus
must
prepar
evalu
suitabl
vaccin
product
ensur
time
avail
virus
suitabl
growth
properti
crucial
step
ensur
suffici
quantiti
vaccin
produc
time
administr
prior
next
influenza
season
although
cell
cultur
steadili
replac
use
embryon
egg
primari
isol
virus
candid
vaccin
virus
must
still
isol
directli
egg
accord
current
regulatori
requir
limit
avail
egg
isol
particularli
recent
virus
gener
grow
poorli
egg
led
establish
cooper
research
develop
agreement
crada
similar
agreement
vaccin
industri
number
whocc
increas
avail
egg
isol
vaccin
use
gisr
vaccin
viru
select
process
necessarili
involv
seri
collabor
step
includ
select
prototyp
antigen
variant
suitabl
vaccin
virus
provis
standard
reagent
erl
process
thu
impact
directli
upon
subsequ
author
vaccin
composit
nation
region
regulatori
author
upon
largescal
product
vaccin
manufactur
mismatch
occasion
occur
result
emerg
variant
strain
shortli
recommend
made
highlight
one
unavoid
consequ
current
vaccin
develop
product
constraint
nevertheless
retrospect
studi
shown
except
vaccin
viru
recommend
close
match
influenza
virus
circul
follow
influenza
season
addit
follow
outofseason
emerg
pandem
viru
close
integr
system
demonstr
uniqu
abil
rapidli
orchestr
develop
provis
appropri
suitabl
attenu
candid
vaccin
virus
pandem
vaccin
product
global
influenza
surveil
alway
present
major
challeng
highli
demand
public
health
need
significantli
uneven
distribut
surveil
capac
worldwid
sinc
outbreak
sever
acut
respiratori
syndrom
sar
reemerg
infect
human
pandem
becom
ever
clearer
surveil
prompt
share
virus
inform
central
broad
rang
influenza
prepared
respons
activ
although
known
impact
awar
season
influenza
vari
differ
part
world
threat
pose
avian
virus
galvan
influenza
surveil
effort
countri
improv
surveil
acquir
capac
detect
report
unusu
case
influenza
essenti
compon
global
pandem
plan
enshrin
intern
health
regul
success
effort
increas
capac
nic
laboratori
made
number
set
develop
revis
adopt
guidelin
strengthen
nation
region
global
surveil
collabor
way
global
influenza
surveil
also
strengthen
expand
geograph
coverag
collect
data
better
qualiti
exampl
africa
influenza
laboratori
countri
includ
recogn
nic
almost
capac
conduct
rtpcr
diagnosi
influenza
infect
less
two
year
percentag
african
countri
nic
increas
number
countri
influenza
laboratori
markedli
decreas
global
region
nation
train
workshop
assess
donat
led
signific
increas
train
personnel
equip
procur
laboratori
capac
result
increasingli
widespread
use
molecular
techniqu
realtim
rtpcr
genet
sequenc
recent
capacitybuild
activ
includ
train
cours
nic
promot
safe
practic
work
highli
pathogen
influenza
virus
cours
viru
isol
gene
sequenc
antivir
resist
detect
increas
particip
intern
extern
qualiti
assur
programm
extern
qualiti
assess
project
eqap
contribut
mark
improv
laboratori
profici
effort
enabl
effect
respons
emerg
pandem
mani
countri
howev
pandem
also
reveal
signific
limit
analysi
integr
epidemiolog
virolog
surveil
data
addit
earli
seropreval
survey
conduct
allow
time
assess
extent
impact
pandem
pandem
also
reveal
signific
gap
laboratori
infrastructur
personnel
equip
procur
fund
particularli
develop
countri
improv
train
area
webbas
integr
analys
clinic
epidemiolog
virolog
data
implement
care
must
taken
ensur
activ
conduct
expens
detect
character
virusshar
activ
less
wellresourc
set
identifi
research
prioriti
influenza
surveil
respons
includ
evalu
tempor
geograph
circul
influenza
virus
burden
influenza
set
establish
sound
evid
base
support
develop
updat
nation
region
global
polici
plan
guidelin
turn
could
lead
greater
accept
use
influenza
vaccin
particularli
season
vaccin
assist
develop
vaccin
polici
primari
requir
nic
remain
prompt
diagnosi
influenza
infect
time
share
clinic
specimen
viru
isol
especi
obtain
unusu
sever
fatal
case
back
appropri
epidemiolog
clinic
inform
procedur
place
ensur
increasingli
predomin
use
molecular
diagnost
techniqu
particularli
realtim
rtpcr
advers
affect
time
isol
forimprov
influenza
vaccin
viru
select
blackwel
publish
ltd
influenza
respiratori
virus
ward
virus
improv
commun
nic
whocc
best
facilit
prompt
viru
share
includ
discuss
constraint
face
could
improv
coordin
avoid
potenti
delay
systemat
approach
engag
nic
inform
expertis
would
also
lead
signific
benefit
approach
like
facilit
number
develop
use
webbas
tool
exampl
nic
enhanc
capabl
current
strengthen
collabor
character
virus
aid
earli
assess
signific
genet
antigen
chang
share
detail
virolog
inform
especi
ha
sequenc
select
virus
either
directli
via
public
databas
technolog
advanc
nation
pattern
seroposit
circul
influenza
virus
may
also
becom
avail
time
basi
could
thu
guid
vaccin
use
particularli
import
given
increas
emphasi
place
assess
vaccin
effect
comprehens
nic
summari
report
forward
prior
consult
also
provid
highli
benefici
addit
data
inform
recommend
vaccin
composit
overcom
logist
obstacl
safe
effici
ship
clinic
specimen
viru
isol
whocc
shipment
fund
project
establish
project
provid
support
nic
influenza
laboratori
countri
arrang
transport
specimen
isol
along
guarante
cold
chain
especi
set
sever
financi
infrastructur
constraint
direct
result
project
associ
infecti
substanc
ship
workshop
conduct
region
signific
increas
number
countri
share
specimen
isol
especi
follow
outbreak
pandem
furthermor
expans
harmon
inform
current
provid
accompani
standard
ship
form
includ
inform
clinic
outcom
patient
vaccin
statu
recent
travel
histori
would
greatli
enhanc
understand
epidemiolog
context
associ
spread
virus
better
understand
divers
evolut
anim
influenza
virus
essenti
evalu
pandem
risk
pose
subtyp
current
caus
sporad
human
infect
inform
select
candid
vaccin
virus
emerg
particular
led
establish
oiefao
network
expertis
anim
influenza
offlu
worldwid
network
approxim
laboratori
institut
coordin
global
surveil
anim
influenza
number
joint
whoofflu
technic
initi
influenza
humananim
interfac
conduct
includ
success
collabor
pandem
reciproc
particip
annual
meet
taken
place
remain
howev
consider
scope
improv
coordin
collabor
anim
influenza
surveil
sector
especi
collect
analysi
antigen
genet
data
time
exchang
repres
virus
refer
reagent
conduct
serolog
studi
human
exposur
zoonot
infect
influenza
import
diseas
mani
avian
mammalian
speci
seriou
econom
consequ
livestock
industri
potenti
advers
impact
human
food
suppli
despit
anim
influenza
surveil
coverag
limit
shortag
epidemiolog
data
circul
variou
virus
differ
countri
effort
way
establish
trigger
initi
enhanc
surveil
go
beyond
anim
diseas
notif
sporad
human
infect
although
increas
understand
interrelationship
anim
human
influenza
need
integr
surveil
full
collabor
nation
global
level
current
constrain
number
practic
fund
regulatori
polici
issu
maintain
regular
dialogu
base
upon
mutual
interest
differ
network
import
public
health
activ
may
also
help
enhanc
sustain
anim
influenza
surveil
particular
set
formal
collabor
mechan
might
allow
improv
integr
anim
viru
data
candid
vaccin
viru
select
process
increas
awar
content
extent
use
anim
influenza
vaccin
would
also
aid
understand
impact
viru
evolut
rang
laboratori
assay
techniqu
provid
complementari
inform
chang
antigen
genet
characterist
influenza
virus
need
select
appropri
influenza
vaccin
virus
howev
inher
limit
biolog
assay
use
signific
variat
result
obtain
differ
laboratori
complic
collat
definit
interpret
data
hai
test
outlin
previous
simpl
rapid
reproduc
surrog
assay
viru
neutral
wide
use
measur
antigen
relationship
differ
virus
well
antibodi
respons
infect
vaccin
addit
test
provid
basi
current
quantit
correl
protect
infect
serum
hai
antibodi
titr
use
standard
inactiv
vaccin
howev
variat
physic
characterist
rbc
obtain
differ
speci
differ
receptorbind
properti
differ
virus
influenc
sensit
util
assay
furthermor
chang
receptorbind
affin
specif
associ
adapt
antigen
drift
isol
passag
virus
egg
cell
cultur
may
also
affect
hai
titr
standard
laboratori
also
prove
difficult
assay
current
suitabl
use
fulli
autom
system
rang
practic
refin
attempt
develop
synthet
rbc
exampl
use
glycanco
bead
unsuccess
given
current
limit
knowledg
princip
natur
receptor
influenza
virus
approach
unlik
circumv
virusdepend
shortcom
assay
base
upon
natur
rbc
therefor
like
remain
primari
approach
antigen
character
forese
futur
recent
develop
base
use
panel
recombin
ha
offer
altern
supplementari
microtitr
microarray
bindingassay
format
assess
antibodi
specif
antibodi
inhibit
haglycan
receptor
interact
although
approach
rel
expens
requir
high
degre
skill
implement
potenti
highli
suit
autom
time
may
reduc
need
viru
isol
addit
format
readili
adapt
incorpor
biosensor
technolog
provid
quantit
analys
bind
characterist
number
assay
current
valid
use
ferret
human
antisera
contribut
antibodi
viru
na
confer
protect
follow
natur
infect
vaccin
still
well
understood
studi
na
antigen
variat
limit
na
content
influenza
vaccin
current
standard
although
neuraminidas
inhibit
nai
assay
conduct
routin
past
cumbersom
perform
complic
rel
low
level
antibodi
na
postinfect
ferret
sera
interfer
antibodi
ha
number
differ
nai
microtitr
assay
format
recent
develop
use
correl
antigen
chang
sequenc
variat
na
compon
provid
precis
inform
evolut
na
assess
na
antibodi
respons
follow
vaccin
improv
understand
antigen
drift
na
role
antina
antibodi
confer
immun
might
signific
implic
vaccin
viru
select
vaccin
develop
microneutr
mn
assay
base
measur
viru
replic
cell
viabil
na
activ
provid
import
adjunct
hai
test
antigen
character
mn
assay
gener
sensit
measur
broader
repertoir
function
antibodi
neutral
viral
replic
potenti
advantag
evalu
human
serolog
respons
addit
comparison
mn
hai
test
measur
antibodi
respons
vaccin
individu
shown
consist
degre
correl
confirm
util
mn
assay
analys
human
antibodi
respons
vaccin
compon
techniqu
simplifi
assay
format
make
readili
applic
routin
test
lowtitr
virus
investig
effort
way
use
mn
assay
b
virus
facilit
use
mn
assay
overcom
variabl
natur
interact
virus
rbc
henc
interpret
anomal
hai
result
complic
vaccin
viru
select
pseudotyp
viru
neutral
assay
may
also
offer
advantag
scale
standard
convent
mn
assay
measur
serolog
respons
particular
virus
especi
highli
pathogen
virus
furthermor
ongo
improv
autom
potenti
enabl
labourintens
mn
assay
appli
largescal
serolog
analysi
epitop
map
use
genom
fragment
phage
display
librari
provid
anoth
power
techniqu
dissect
fine
specif
antibodi
respons
vaccin
infect
allow
better
assess
qualiti
protect
immun
respons
aid
develop
addit
correl
immun
encourag
perform
seroepidemiolog
survey
assess
impact
influenza
popul
countri
support
establish
wellcharacter
serum
bank
agestratifi
repres
sera
nation
region
global
resourc
current
advantag
gisr
serolog
activ
undertaken
support
vaccin
viru
select
includ
use
share
serum
panel
common
antigen
frequent
consensu
obtain
particip
whocc
erl
limit
includ
larg
variabl
hai
data
requir
antibodi
standard
need
mn
assay
resolv
inconsist
avail
antibodi
standard
would
enhanc
compar
serolog
data
gener
differ
laboratori
countri
also
facilit
comparison
antibodi
respons
differ
vaccin
increas
attent
influenza
vaccin
effect
studi
lead
avail
realtim
data
compar
clinic
benefit
degre
antigen
improv
influenza
vaccin
viru
select
blackwel
publish
ltd
influenza
respiratori
virus
related
vaccin
circul
virus
studi
especi
base
upon
laboratoryconfirm
outcom
provid
evid
specif
benefit
vaccin
consist
studi
provid
estim
vaccin
efficaci
success
influenza
season
improv
understand
effect
small
rather
major
antigen
differ
vaccin
circul
virus
clinic
outcom
help
allay
concern
aris
perceiv
vaccin
mismatch
caus
emerg
viru
clade
exhibit
littl
antigen
drift
recent
advanc
highthroughput
genet
sequenc
could
potenti
lead
greatli
enhanc
understand
genet
chang
occur
influenza
virus
evolutionari
interact
occur
cocircul
virus
indepth
analys
precis
mechan
involv
evolut
epidemiolog
influenza
would
requir
advanc
bioinformat
tool
comprehens
mine
data
produc
approach
reveal
exampl
broader
genet
chang
underli
antigen
variat
ha
thu
allow
better
understand
relationship
genet
evolut
antigen
drift
increas
inform
xray
crystallographi
structur
featur
recent
virus
specif
mutant
togeth
develop
comput
model
assist
attempt
predict
like
influenc
amino
acid
substitut
antigen
receptorbind
properti
new
variant
develop
highthroughput
laboratori
system
integr
autom
genet
phenotyp
analys
initi
sampl
access
data
manag
offer
intrigu
prospect
futurist
standard
virtual
network
viru
character
epidemiolog
context
system
broad
implic
vaccin
viru
select
also
organ
conduct
global
influenza
surveil
extrem
import
develop
deploy
integr
activ
gisr
numer
mathemat
model
techniqu
use
gain
insight
mechan
underli
evolut
epidemiolog
influenza
virus
exampl
exploratori
model
develop
gener
test
variou
hypothes
explain
rel
restrict
divers
influenza
virus
term
constrain
antigen
repertoir
explor
underli
natur
immun
also
use
improv
understand
extent
betweensubtyp
betweentyp
competit
potenti
consequ
interact
trend
incid
season
influenza
virus
phylogenet
model
also
use
identifi
chang
select
constraint
relat
antigen
drift
interspeci
transmiss
base
upon
amino
acid
substitut
associ
mammalian
host
adapt
model
may
aid
assess
pandem
potenti
avian
anim
virus
phylodynam
model
base
upon
avail
sequenc
data
supplement
antigen
data
alreadi
success
use
trace
emerg
new
antigen
genet
variant
track
geograph
spread
howev
absenc
greatli
improv
understand
underli
evolutionari
biolog
mechan
process
involv
capac
current
mathemat
model
techniqu
predict
time
natur
futur
antigen
genet
chang
limit
intrins
stochast
natur
influenza
evolut
may
make
predict
model
extrem
challeng
chang
occur
short
time
scale
applic
simpler
nonmechanist
statist
algorithm
use
basi
antigen
cartographi
like
use
facilit
vaccin
viru
select
attempt
develop
predict
model
exist
complex
dynam
model
influenza
evolut
transmiss
predict
model
might
present
better
suit
use
understand
possibl
longterm
effect
vaccin
optim
time
locat
focus
surveil
effort
predict
possibl
consequ
emerg
novel
viru
eventu
model
abl
take
advantag
integr
immunolog
antigen
surveil
data
develop
predict
shortterm
dynam
specif
locat
new
influenza
vaccin
technolog
implic
vaccin
viru
select
regulatori
manufactur
process
howev
potenti
requir
tailor
viru
select
process
specif
type
vaccin
unlik
crucial
issu
especi
advanc
vaccin
technolog
speed
product
lead
greater
flexibl
time
recommend
although
liveattenu
vaccin
yet
univers
licens
current
vaccin
composit
recommend
process
use
howev
antibodi
respons
good
correl
protect
vaccin
identif
true
correl
might
affect
requir
annual
updat
sever
quadrival
vaccin
also
develop
contain
repres
strain
two
influenza
b
viru
lineag
b
victoria
b
yamagata
togeth
influenza
virus
rais
number
issu
could
affect
vaccin
suppli
includ
possibl
two
poorli
grow
vaccin
virus
like
variabl
impact
fourth
compon
vaccin
yield
time
manufactur
priorit
influenza
b
lineag
virus
context
trival
quadrival
vaccin
product
need
fourth
set
reagent
adjuv
vaccin
licens
primari
aim
induc
better
immun
respons
certain
age
group
allow
antigen
spare
although
specif
intent
provid
broader
spectrum
immun
circumv
need
annual
vaccin
updat
differ
product
like
show
differ
breadth
respons
provid
recommend
relat
productspecif
crossreact
success
influenza
season
unlik
feasibl
option
gisr
addit
variou
type
recombin
vaccin
develop
includ
protein
subunit
dna
vector
vlp
vaccin
none
present
licens
case
nonhabas
vaccin
differ
guidelin
appli
vaccin
like
impact
current
vaccin
viru
select
process
variou
way
depend
upon
precis
type
mechan
protect
level
protect
afford
immun
na
receiv
continu
interest
current
compon
includ
part
candid
vaccin
viru
select
basi
sequenc
antigen
standard
na
compon
would
requir
antigen
character
viru
select
process
antigen
chang
na
absenc
correspond
chang
ha
antigen
may
necessit
updat
vaccin
composit
vaccin
ha
variant
select
may
becom
less
crucial
current
vaccin
although
highgrowth
reassort
use
manufactur
influenza
vaccin
compon
mani
year
yield
variabl
continu
need
identifi
molecular
determin
high
yield
engin
reliabl
reproduc
product
process
revers
genet
use
unit
state
produc
viru
reassort
liveattenu
vaccin
also
use
produc
attenu
candid
vaccin
virus
suitabl
inactiv
vaccin
manufactur
approach
howev
less
success
classic
reassort
obtain
suitabl
pandem
vaccin
viru
emphas
need
investig
applic
revers
genet
routin
provis
suitabl
vaccin
virus
follow
licens
cell
cultur
vaccin
feasibl
isol
season
vaccin
virus
qualifi
cell
line
evalu
collabor
involv
number
whocc
erl
crada
vaccin
manufactur
studi
provid
basi
introduct
univers
qualifi
cell
cultur
system
provid
mammalian
cellderiv
season
influenza
candid
vaccin
virus
would
result
greater
choic
candid
especi
recent
virus
may
provid
greater
flexibl
respond
late
emerg
variant
necessit
vaccin
composit
chang
viru
isol
would
subject
undesir
eggselect
chang
would
potenti
provid
better
match
natur
viru
howev
rel
merit
egg
cell
cultur
candid
vaccin
virus
still
rigor
evalu
guidanc
qualiti
assur
aspect
alreadi
publish
european
medicin
agenc
ema
final
new
ema
regulatori
guidelin
may
accompani
technic
document
harmon
regulatori
approach
worldwid
engag
regulatori
author
vaccinemanufactur
nation
vaccin
manufactur
erl
also
collabor
evalu
cell
culturebas
reagent
use
singl
radial
immunodiffus
srid
potenc
test
due
complet
earli
addit
despit
intern
consensu
key
qualiti
specif
pandem
influenza
vaccin
reagent
calibr
major
candid
vaccin
use
convent
potenc
test
becam
avail
immedi
prior
initi
clinic
trial
case
candid
vaccin
avail
ahead
reagent
although
nation
author
prove
flexibl
accept
use
valid
altern
potenc
test
allow
clinic
trial
proceed
newer
method
highperform
liquid
chromatographi
hplc
mass
spectrometri
evalu
gisr
long
histori
success
recommend
influenza
vaccin
composit
close
match
combin
virus
circul
subsequ
influenza
season
base
upon
voluntari
particip
mani
constitu
partner
gisr
enjoy
strong
institut
government
support
global
influenza
surveil
foundat
vaccin
viru
select
process
effort
enhanc
strengthen
nation
region
global
laboratori
capac
virolog
surveil
repres
viru
share
must
continu
part
improv
integr
virolog
diseas
surveil
data
key
aim
help
build
foundat
futur
studi
impact
burden
influenza
worldwid
strengthen
pandem
influenza
prepared
collabor
gisr
veterinari
laboratori
organ
offlu
relat
zoonot
influenza
infect
greatli
enhanc
includ
develop
appropri
candid
human
vaccin
virus
anim
virus
howev
remain
consider
scope
improv
area
includ
time
exchang
inform
virus
reagent
strengthen
technic
collabor
level
although
antigen
character
promptli
forward
viru
isol
remain
central
criterion
select
influenza
vaccin
virus
forese
futur
technolog
develop
advanc
recombin
dna
protein
technolog
highthroughput
sequenc
advanc
bioinformat
tool
inevit
impact
current
gisr
surveil
viru
select
activ
interest
global
public
health
import
integr
gisr
system
appropri
inform
data
gener
variou
network
use
emerg
technolog
antigen
cartographi
adopt
gisr
recent
year
mean
integr
hai
data
differ
laboratori
allow
statist
comparison
visual
display
develop
new
statist
algorithm
complement
use
antigen
cartographi
may
facilit
vaccin
viru
select
greater
emphasi
place
conduct
human
serolog
studi
incorpor
use
antibodi
standard
improv
compar
result
studi
would
improv
current
understand
preval
spread
influenza
complement
develop
improv
epidemiolog
model
greater
collabor
effort
need
gener
randomli
sampl
repres
integr
serolog
epidemiolog
evolutionari
data
provid
snapshot
host
viral
popul
suitabl
model
hypothes
viru
evolut
host
immun
applic
advanc
techniqu
dissect
fine
specif
antibodi
respons
vaccin
infect
also
lead
improv
understand
qualiti
protect
immun
respons
aid
develop
addit
correl
immun
recent
collabor
gisr
extern
partner
includ
academ
institut
vaccin
manufactur
result
increas
avail
egg
isol
highgrowth
reassort
new
approach
gener
highgrowth
vaccin
virus
involv
use
revers
genet
qualifi
cell
cultur
continu
evalu
develop
altern
method
vaccin
potenc
test
continu
support
effort
increas
reliabl
timeli
global
influenza
vaccin
suppli
new
vaccin
type
current
develop
may
allow
flexibl
time
recommend
vaccin
viru
composit
convers
alter
viru
select
process
addit
inform
may
need
relat
newgener
vaccin
type
differ
composit
mechan
protect
gisr
vaccin
viru
select
process
lie
heart
global
effort
address
constantli
evolv
threat
pose
influenza
decad
highli
collabor
complex
process
ensur
continu
suppli
write
group
effect
season
vaccin
abl
respond
rapidli
emerg
pandem
current
limit
constraint
inher
process
overcom
ongo
effort
gisr
partner
must
continu
identifi
improv
har
new
technolog
strengthen
collabor
continu
central
role
develop
coordin
worldwid
expertis
meet
increas
public
health
need
influenza
vaccin
support
process
conven
period
intern
consult
improv
influenza
vaccin
viru
select
annex
process
influenza
vaccin
viru
select
develop
diagram
show
individu
step
select
candid
vaccin
virus
develop
standard
reagent
season
influenza
potenti
influenza
pandem
essenti
equival
season
vaccin
timelin
step
collect
isol
thorough
antigen
genet
character
recent
viru
isol
continu
throughout
year
step
comparison
recognit
repres
recent
virus
vaccineinduc
antibodi
human
sera
conduct
week
biannual
vaccin
consult
meet
step
candid
virus
vaccin
use
review
select
highgrowth
reassort
prepar
character
follow
identif
potenti
antigen
variant
step
sole
dictat
recommend
biannual
vaccin
viru
consult
step
evalu
growth
properti
conduct
time
manner
around
time
vaccin
viru
consult
prior
author
vaccin
composit
nation
author
step
prepar
standard
reagent
new
vaccin
compon
initi
particular
vaccin
viru
select
follow
recommend
inform
consult
improv
influenza
vaccin
viru
select
june
organ
viru
monitor
vaccin
support
vmv
unit
particip
collabor
centr
influenza
erl
nation
influenza
centr
nation
control
laboratori
nation
regulatori
author
academ
veterinari
institut
influenza
vaccin
manufactur
collabor
organ
accord
polici
member
write
group
assist
develop
meet
report
complet
declar
interest
expert
declar
evalu
secretariat
prior
consult
member
write
group
declar
follow
person
current
recent
within
last
year
financi
interest
relev
subject
area
group
data
need
plo
curr
influenza
revis
decemb
